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 Quantification of the 15 major human bile acids and their precursor 
7α-hydroxy-4-cholesten-3-one in serum by liquid chromatography-
tandem mass spectrometry 
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Abstract 
 
 
Bile acids are increasingly gaining attention since they were discovered to be 
activators of the transcription factor farnesoid X receptor (FXR) in addition to their 
well-established role in dietary lipid emulsification. Moreover, the differential 
activation potency of bile acids on FXR, which is due to structural variation of the 
ligands, generates the need for new analytical tools that are sensitive and specific 
enough to quantify the individual species of this complex class of compounds. 
Because bile acids undergo enterohepatic circulation, the additional assessment of a 
bile acid precursor as a marker for bile acid biosynthesis is used to differentiate 
between newly synthesised bile acids and bile acids reabsorbed from the intestine. 
This paper describes two new methods using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) for the quantification of the major unconjugated bile acids 
in human serum (cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic 
acid and ursodeoxycholic acid) with their glycine- and taurine-conjugates as well as 
their precursor 7alpha-hydroxy-4-cholesten-3-one (C4). Intra- and inter-day variation 
was less than 12% and accuracy was between 84% and 102% for all analytes. 
Extraction recovery was between 78% and 100% for the bile acids whereas it was 
62% for C4 and limit of quantification values ranged from 2-50nmol/l for all 
compounds. 
These two methods have the practical advantage of requiring low sample volume 
(100μl serum for each method) and identical eluents, stationary phase as well as 
ionisation technique, so that they can be used in a combined way. Moreover, they 
provide information on the composition of the bile acid pool on one hand and on the 
relative amount of newly synthesised bile acids on the other, which taken together, 
gives new insights in the investigation of bile acid metabolism. 
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1. Introduction 
 
 
Abbreviations1 
 
Bile acids play an important physiological role in the elimination of cholesterol from 
the human body since they represent the main degradation pathway for this poorly 
soluble lipid. Moreover, their emulsifying properties are essential for digestion of 
dietary fat and lipophilic vitamins. In the last decade, bile acids were additionally 
discovered to be natural ligands of the farnesoid X receptor (FXR) [1-3], a nuclear 
transcription factor through which they regulate their own biosynthesis via a negative 
feedback. Moreover, it is now well established that FXR activation by bile acids 
results in the regulation of various genes involved not solely in bile acid homeostasis 
but also in cholesterol, triglyceride and glucose metabolism [4-9]. Therefore, bile 
acids have gained much attention since they might be of interest as biomarkers or as 
pharmacological targets in several intestinal and metabolic conditions ranging from 
Crohn’s disease to metabolic syndrome [5,10-12]. 
Biosynthesis of bile acids mainly takes place in the liver. Oxidation of the cholesterol 
steroid core by the microsomal cholesterol 7α-hydroxylase (CYP7A1) in the classical 
pathway represents the rate-limiting step in bile acid biosynthesis and leads to the 
formation of the precursor 7α-hydroxycholesterol. The final products of the enzymatic 
cascade are the two primary bile acids cholic acid and chenodeoxycholic acid, which 
are conjugated to an amino acid, usually glycine or taurine, prior to excretion. Once 
they are in the intestine, a fraction of conjugated cholic acid and chenodeoxycholic 
acid are deconjugated and/or converted to secondary bile acids by intestinal bacteria. 
The mixture of primary and secondary bile acids formed in this way is reabsorbed 
                                                 
1 C4, 7alpha-hydroxy-4-cholesten-3-one; CA, cholic acid; CDCA, chenodeoxycholic 
acid; CYP7A1, cholesterol 7α-hydroxylase; DCA, deoxycholic acid; ESI, electrospray 
ionisation; FDA, Food and Drug Administration; FXR, farnesoid X receptor; GCA, 
glycocholic acid; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic 
acid; GLCA, glycolithocholic acid; GUDCA, glycoursodeoxycholic acid; LCA, 
lithocholic acid; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LOQ, 
limit of quantification; QC, quality control; SPE, solid-phase extraction; TCA, 
taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; 
TLCA, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, 
ursodeoxycholic acid 
 
from the small intestine and returns to the liver via the portal system in order to be 
recycled and secreted again into the bile, thus completing the enterohepatic 
circulation [5]. The bile acid pool of an organism subsequently contains twenty or 
more different species varying in their abilities to activate FXR, in their susceptibilities 
to be metabolised by the intestinal bacteria flora and in their half-lives in the 
enterohepatic circulation. In order to have a better overview on the amount of newly 
synthesised bile acids out of cholesterol (in contrast to bile acids found in the 
circulation after reabsorption from the intestine), quantification of a bile acid precursor 
may be used. In this regard, it was shown that plasma levels of 7α-
hydroxycholesterol, the precursor for the classical pathway, reflect bile acid synthesis 
in vivo [13]. However, this steroid may be formed from cholesterol as an artefact due 
to lipid peroxidation and therefore a sample might contain undefined amounts of 7α-
hydroxycholesterol of non-enzymatic origin 7α-hydroxy-4-cholesten-3-one (C4), the 
immediate enzymatic product of 7α-hydroxycholesterol is not formed by lipid 
peroxidation and was shown to reflect the activity of CYP7A1 in humans as well. 
Therefore, it can also be used as a marker for bile acid biosynthesis [14-15]. 
Because of the complexity of this class of compounds and their low concentration in 
the peripheral circulation as a result of efficient first-pass extraction by the liver, 
quantification of bile acids requires analytical techniques which offer high sensitivity 
and specificity. Moreover, due to the broad spectrum of activation potencies of the 
various bile acids on FXR, differentiated quantification of these metabolites is needed 
in order to understand the molecular mechanisms in which bile acids are involved. 
This was achieved as chromatographic techniques were coupled to mass 
spectrometry and has led to the expansion of this field of research. In contrast to gas 
chromatography, which requires laborious sample preparation including hydrolysis 
and derivatisation, liquid chromatography coupled with mass spectrometry (LC-
MS(/MS)) nowadays represents the most convenient alternative for this type of 
analysis, as demonstrated by the number of new quantification methods developed in 
the past years for bile acids [16-24] and C4 [12,14,25-26]. 
In this paper, we present two new LC-MS/MS methods for the combined 
quantification in serum of the 15 major human bile acids on one hand and their 
precursor for the classical pathway, namely C4, on the other (Figure 1). The main 
assets of these methods are that they require low sample volume (100μl for each 
method) and that they enable a detailed description of bile acid metabolism since 
they provide information not only on the composition of the circulating bile acid pool 
but also on the amount of newly synthesised bile acids via C4 quantification. 
Moreover, these methods can be combined since they require identical eluents for 
the mobile phase, an identical stationary phase and the same ionisation technique. 
This simplifies the procedure and spares hardware modifications because neither the 
column nor the source needs to be changed between different types of samples. 
Together with another method previously developed in our group for the 
quantification of the bile acid precursor for the alternative biosynthesis pathway, 
namely 27-hydroxycholesterol [27], these tools allow a detailed description of bile 
acid metabolism in humans. 
 
 
2. Experimental 
 
 
2.1 Chemicals 
 
Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic 
acid (LCA), ursodeoxycholic acid (UDCA), glycochenodeoxycholic acid (GCDCA), 
glycodeoxycholic acid (GDCA), taurochenodeoxycholic acid (TCDCA) and 
taurodeoxycholic acid (TDCA) were purchased from Sigma-Aldrich (Buchs, 
Switzerland), whereas the glycine- and taurine-conjugates of CA (GCA and TCA), 
LCA (GLCA and TLCA) and UDCA (GUDCA and TUDCA) were obtained from 
Calbiochem (Darmstadt, Germany). The deuterated bile acid internal standards 
cholic acid-2,2,4,4-d4 (CA-d4) and chenodeoxycholic acid-2,2,4,4-d4 (CDCA-d4) were 
obtained from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA), whereas 
deoxycholic acid-2,2,4,4-d4 (DCA-d4), lithocholic acid-2,2,4,4-d4 (LCA-d4), 
ursodeoxycholic acid-2,2,4,4-d4 (UDCA-d4), glycocholic acid-2,2,4,4-d4 (GCA-d4) and 
glycochenodeoxycholic acid-2,2,4,4-d4 (GCDCA-d4) were purchased from C/D/N 
Isotopes, Inc. (Pointe-Claire, Quebec, Canada). 
The bile acid precursor C4 was purchased from Toronto Research Chemicals, Inc. 
(North York, Ontario, Canada) and its deuterated internal standard 7alpha-hydroxy-4-
cholesten-3-one-25,26,26,26,27,27,27-d7 (C4-d7) was obtained from Medical 
Isotopes, Inc. (Pelham, NH, USA). 
The salts for buffers and methanol were of HPLC grade. Activated charcoal and 
ammonium acetate were purchased from Sigma-Aldrich (Buchs, Switzerland), 
ammonium carbonate was obtained from Scharlau Chemie (Barcelona, Spain), 
methanol was obtained from Honeywell Burdick & Jackson (Seelze, Germany) and 
hydrochloric acid 32% (GR for analysis) was obtained from Merck (Darmstadt, 
Germany). Human serum from healthy volunteers was obtained from PAA 
Laboratories (Pasching, Austria) and purified water was obtained using a central 
water purification installation from Burkhalter (Worblaufen, Switzerland). 
 
 
2.2 Preparation of a bile acid/C4-free serum pool 
 
In order to construct calibration curves in a matrix free from endogenous bile acids 
and C4 but similar to the real sample matrix, serum was mixed overnight with 
100mg/ml activated charcoal, known for its high adsorption capacity. The mixture 
was then centrifuged at 13’000 x g and 10°C for 20min, after which the supernatant 
was collected and centrifuged again. After three centrifugation cycles, the 
supernatant was filtered with a 0.45μm filter and stored at -20°C until analysis. Prior 
to use, newly prepared charcoal treated serum batches were tested for the absence 
of any remaining endogenous bile acids or C4 (data not shown). 
 
 
2.3 Preparation of standard stock solutions 
 
Bile acid standard stock solutions were prepared by dissolving the respective 15 bile 
acids in the appropriate amount of methanol in order to obtain individual stock 
solutions of 5μmol/ml. The 15 individual stock solutions were then pooled together to 
obtain a 100μmol/l solution in methanol, which was further diluted with purified water 
to obtain standard stock solutions containing 25, 10, 5, 0.5 and 0.05μmol/l of each 
bile acid, respectively. 
A 1μmol/ml C4 standard stock solution was prepared by dissolving C4 in the 
appropriate amount of acetonitrile. This solution was further diluted with methanol to 
obtain 0.5, 0.1, 0.05 and 0.01μmol/l standard stock solutions. 
 
 2.4 Preparation of deuterated internal standard stock solutions 
 
The 7 deuterated bile acids were dissolved in the appropriate amount of methanol in 
order to obtain individual 3μmol/ml solutions. These solutions were then pooled 
together to obtain a 75μmol/l solution in methanol, which was further diluted with 
water to obtain an internal standard solution containing 15μmol/l of each deuterated 
bile acid. 
A 1μmol/ml C4-d7 solution was prepared in acetonitrile and further diluted with 
methanol to obtain a 0.1μmol/l C4-d7 internal standard solution. 
 
 
2.5 Sample preparation 
 
Calibrators and quality control samples (QCs) were prepared by adding the 
appropriate amount of the different standard stock solutions to 100μl of charcoal 
treated serum and extracting these using the corresponding sample preparation 
procedure described below. 
 
2.5.1 Sample preparation for the 15 bile acids 
 
100μl serum sample (respectively 100μl charcoal treated serum with defined 
amounts of the appropriate standard stock solution) were mixed with 100μl 
ammonium carbonate buffer 100mM, pH 9.3. The volume was completed to 700μl 
with purified water and 30μl of the 15μmol/l deuterated bile acids internal standard 
solution were added, after which the samples were vortexed. 
Sample preparation was performed by solid-phase extraction (SPE) with 200mg 
Bond Elut C18 cartridges from Varian, Inc. (Palo Alto, CA, USA) using a procedure 
previously described by our group [24], after minor adaptations (mainly reduction of 
sample volume). Pre-conditioning of the cartridges was achieved by activation with 
2ml methanol followed by 2ml purified water and finally 2ml ammonium carbonate 
buffer 100mM, pH 9.3, upon which the sample was loaded onto the cartridge and 
allowed to pass through it by gravity. Thereafter, the cartridge was washed with 2ml 
purified water and dried under vacuum. The retained compounds were eluted with 
3ml of methanol using gravity and the samples were evaporated at 30°C under 
vacuum using a rotavapor from Büchi (Flawil, Switzerland). The residue was 
dissolved in 60μl methanol and mixed with 30μl ammonium acetate buffer 10mM, pH 
6.5, upon which the sample was centrifuged at 13’400 x g and 10°C for 10min. The 
supernatant was collected and 30μl were injected into the LC-MS system for 
analysis. 
 
2.5.2 Sample preparation for C4 
 
100μl serum sample (respectively 100μl charcoal treated serum with defined 
amounts of the appropriate standard stock solution) were mixed with 500μl purified 
water and 50μl of the 0.1μmol/l C4-d7 internal standard solution. The methanol 
volume (including 50μl internal standard solution and various amounts of standard 
stock solutions) was completed to 150μl in all samples in order to avoid variations 
due to different methanol contents while loading the samples on the SPE cartridges. 
Finally, 60μl of 1M hydrochloric acid were added to all samples and these were 
vortexed immediately afterwards in order to loosen the C4 fraction presumably bound 
to plasma proteins. 
Sample preparation was performed using the same solid-phase extraction cartridges 
as for the bile acids sample preparation. Pre-conditioning of the cartridges was 
achieved by activation with 2ml methanol followed by 2ml purified water, upon which 
the sample was loaded onto the cartridge and allowed to pass through it by gravity. 
The cartridge was washed and samples were eluted and evaporated as described in 
the bile acid sample preparation procedure (2.5.1). The residue was dissolved in 80μl 
methanol and mixed with 10μl ammonium acetate buffer 10mM, pH 6.5, upon which 
the sample was centrifuged at 13’400 x g and 10°C for 10min. The supernatant was 
collected and 30μl were injected into the LC-MS system for analysis. 
 
 
2.6 Quantification 
 
The calibration domain for the 15 bile acids ranged from 0.02μmol/l to 50μmol/l and 
could be extended to 100μmol/l without affecting linearity by adding two additional 
calibrators if required (for highly concentrated samples). Due to the large calibration 
range, the intercept contributed significantly to the peak area ratios of low 
concentrated samples. Therefore samples with concentrations above 5μmol/l were 
calculated using all 6 (respectively 8) calibrators 0.02, 0.5, 5, 10, 30 and 50μmol/l 
(respectively 75 and 100μmol/l), whereas samples with concentrations below 5μmol/l 
were calculated using only the first 3 calibrators. Samples with concentrations below 
0.02μmol/l as well as samples for which the peak area ratio was below the absolute 
value of the intercept of its respective 3 points calibration curve were calculated by 
proportional conversion using the respective peak area ratio of the first calibration 
standard. Since deuterated internal standards with identical structure were not 
commercially available for each of the 15 bile acids at the time the method was 
developed, those lacking an identical deuterated homologue were attributed the 
corresponding unconjugated deuterated bile acid (Table 1). Although the deuterated 
bile acids used as internal standards were of high purity, they contained a fraction of 
corresponding undeuterated bile acid which contributed to the peak area of the 
analytes in the samples as well as in the calibrators and the QCs. The percentage of 
undeuterated bile acids contained in the various internal standards varied from 0.1% 
to 1.2% and this effect was corrected by subtracting a defined percentage of the 
internal standard peak from the corresponding undeuterated analyte peak in every 
analysis. 
The calibration domain for C4 ranged from 0.01μmol/l to 0.4μmol/l and sample 
concentration was calculated similarly as described above. Samples with 
concentrations above 0.05μmol/l were calculated using all 6 calibrators 0.01, 0.02, 
0.05, 0.1, 0.2 and 0.4μmol/l, whereas samples with concentrations below 0.05μmol/l 
were calculated using only the 3 first calibrators. Samples with concentrations below 
0.01μmol/l as well as samples for which the peak area ratio was below the absolute 
value of the intercept of its respective 3 points calibration curve were calculated by 
proportional conversion using the respective peak area ratio of the first calibration 
standard. Since only insignificant amounts of undeuterated C4 impurity could be 
detected in the C4-d7 internal standard solution, the peak area of C4 did not need to 
be corrected in contrast to that of bile acids. 
 
 
2.7 Instrumentation 
 
The LC-MS system consisted of an HTC PAL autosampler from CTC Analytics 
(Zwingen, Switzerland) coupled with a Rheos 2200 HPLC pump from Flux 
Instruments (Reinach, Switzerland) and a TSQ Quantum Access mass spectrometer 
from Thermo Scientific (Waltham, MA, USA). Separation was achieved using a 
125mm x 2.0mm Uptisphere C18 5μm particle size ODB column from Interchim 
(Montluçon, France), which was protected by a 10mm x 2.0mm modulo-cart QS 
guard column also from Interchim. Data acquisition was performed using Xcalibur 
software (version 2.0.6) from Thermo Scientific. 
 
 
2.8 Separation, ionisation and detection conditions 
 
Mobile phase for both methods consisted of methanol (eluent A) and 10mM 
ammonium acetate buffer at pH 6.5 (eluent B). 
For separation of the bile acids, the eluents were set to 65% A and 35% B during the 
first 10min, after which the proportions were changed within 2min to 70% A and 30% 
B and maintained for 4min. After 16min of analysis, the proportions were changed 
again within 1min to 80% A and 20% B and maintained for 8min. At 25min, the 
proportions were changed to 100% A and maintained for 5min in order to flush the 
column, upon which the conditions were set to the beginning proportions of 65% A 
and 35% B for 20min to equilibrate the chromatographic column. The flow rate was 
set to 300μl/min during the whole analysis. 
The separation of the more hydrophobic C4 was achieved with a mobile phase 
containing 93% A and 7% B at a flow rate of 250μl/min. After 10min the column was 
flushed for 5min with 400μl/min of eluent A and finally the column was equilibrated for 
10min at a flow rate of 300μl/min with the beginning proportions of 93% A and 7% B. 
In both methods, ionisation was performed using an electrospray ionisation (ESI) 
source, which was operating in the negative mode for bile acids and in the positive 
mode for C4. Ionisation parameters were tuned for the different compounds and 
optimal conditions are shown in Table 2. The tube lens and collision energy values 
were individually optimised for each analyte and are reported in Table 1. Collision 
pressure was set to the default value of 1.5mTorr. Scan time was set to 0.05s for the 
bile acids and to 0.5s for C4, while scan width was set to 0.002m/z for both methods. 
Due to the lack of stable fragments for unconjugated bile acids, their detection was 
performed in the pseudo-selected reaction monitoring mode. This detection mode 
uses low collision energy, which does not fragment the parent ion, but decreases the 
background noise and therefore leads to a better signal-to-noise ratio. In contrast, all 
of the conjugated bile acids as well as C4 showed reproducible fragments which are 
reported in Table 1. 
 
 
2.9 Method validation 
 
A detailed validation procedure was performed according to the Food and Drug 
Administration (FDA) guidelines [28]. 
 
2.9.1 Linearity 
 
Defined amounts of standard stock solutions were added to charcoal treated serum 
for preparation of 6 calibration points ranging from 0.02μmol/l to 50μmol/l for bile 
acids and from 0.01μmol/l to 0.4μmol/l for C4. The samples were extracted as 
described in paragraph 2.5.1 and 2.5.2 respectively. Calibration curves were plotted 
as the peak area ratio of the respective bile acid over its internal standard against the 
nominal concentration of the calibrator. The line of best fit was determined by least 
square linear regression for the lower calibration domain (3 lowest calibrators) as well 
as for the entire calibration domain for both methods and for six freshly prepared 
calibration curves. Calculation of the mean correlation coefficient was used to assess 
linearity. 
 
2.9.2 Precision and accuracy 
 
In order to assess intra-day precision and accuracy, six QCs of a low and of a high 
concentration (0.5μmol/l and 30μmol/l for bile acids versus 0.02μmol/l and 0.2μmol/l 
for C4) were extracted and analysed using a freshly prepared calibration curve on a 
given day. Additional QCs for each the low and the high concentrations were also 
analysed on five different days, each time with a freshly prepared calibration curve, in 
order to assess inter-day precision and accuracy. Precision of the method was 
represented by the coefficient of variation while accuracy was obtained by expressing 
the mean of the measured concentrations as a percentage of the nominal 
concentration. 
 
2.9.3 Recovery 
 
Since matrix constituents are known to influence the extraction process, the recovery 
experiment was performed using untreated serum instead of a charcoal treated 
serum in order to have extraction conditions as close as possible to those of real 
samples. 
In order to assess efficiency of the extraction procedure, twelve serum samples were 
extracted for each a low and a high concentration (0.5μmol/l and 30μmol/l for bile 
acids versus 0.02μmol/l and 0.2μmol/l for C4). From these twelve samples, six were 
spiked with the appropriate amount of standard stock solutions and internal 
standards before extraction. The six remaining samples were extracted as blanks 
and spiked with the same amount of standard stock solutions and internal standards 
after the extraction. Six additional blank samples containing only endogenous bile 
acids or C4 were extracted without addition of any standard stock solutions or 
internal standards. Thereafter all samples were evaporated and dissolved in mobile 
phase according to 2.5.1 and 2.5.2 respectively. After correction of the spiked serum 
samples by subtraction of endogenous amounts of the respective analyte, recovery 
was obtained by expressing the mean peak area of samples spiked before extraction 
as a percentage of that of samples spiked after extraction. 
 
2.9.4 Limit of quantification 
 
QCs were spiked with concentrations ranging from 0.002μmol/l to 0.05μmol/l for the 
bile acids and 0.001μmol/l to 0.01μmol/l for C4. Five replicates were extracted and 
analysed for each concentration and limit of quantification (LOQ) was determined as 
being the lowest concentration at which the analyte could be quantified with sufficient 
precision and accuracy. 
 
2.9.5 Matrix effects 
 
Matrix effects were assessed by two different methods, in both a quantitative and a 
qualitative manner. Because of the major role played by matrix components, these 
experiments were performed using untreated serum instead of charcoal treated 
serum. 
In order to assess matrix effects in a quantitative manner, six blank serum samples 
were extracted using the procedures described for bile acids and C4 respectively. 
After extraction, three samples were spiked with defined amounts of standard stock 
solutions (10μmol/l for bile acids versus 0.1μmol/l for C4) and internal standards, 
while the remaining three samples were kept as blank samples. Simultaneously, 
identical amounts of standard stock solutions and internal standards were pipetted 
into three clean vials. All samples were then evaporated and dissolved in mobile 
phase according to 2.5.1 and 2.5.2 respectively. After correction of the spiked serum 
samples by subtraction of endogenous amounts of the respective analyte, 
quantitative matrix effects were assessed by expressing the peak area of spiked 
serum samples (with matrix) as a percentage of the peak area of samples containing 
only the pure standard stock solutions (without matrix). 
The qualitative evaluation of potential ion suppression or enhancement effects due to 
matrix components was preformed by post-column infusion of a solution containing 
the analyte of interest while an extracted blank serum sample was simultaneously 
injected by the autosampler. Matrix components interfering with the ionisation 
process show an increase (ion enhancement) or more often a decrease (ion 
suppression) in the signal.  
 
 
3. Results and discussion 
 
 
3.1 Preparation of standard stock solutions 
 
During method development, a rapid decrease in peak intensity was observed in 
aqueous solutions of C4 (data not shown). This decrease was probably due to poor 
aqueous solubility of C4 because it was not observed when C4 was dissolved in 
methanol. Therefore all C4 standard stock solutions were prepared in methanol, 
although this should be avoided as much as possible when using solid-phase 
extraction. Nevertheless, in order to have identical extraction conditions, the 
methanol volume was completed to 150μl in all C4 samples. In contrast to C4, bile 
acids were dissolved in water and showed no decrease in peak intensity. 
 
 
3.2 Sample preparation 
 
Our new methods each required only 100μl of serum sample, which was less than for 
many of the existing methods [12,14,16,20,22-24] although methods for 
quantification of C4 in even smaller sample volumes exist [25-26]. A low sample 
volume represents an important advantage if the method is to be adapted for 
analysis of mouse samples (muricholic acids), since mice have a very small blood 
volume. In addition, our C4 method offers the advantage of requiring a rather short 
sample preparation in comparison to other existing methods [14,25-26] and no 
derivatization [25-26]. However, in order for these methods to be improved, efforts 
should be made to find a combined extraction procedure for bile acids and C4, which 
would reduce sample volume to only 100μl instead of twice 100μl and would lead to a 
shorter total analysis time. This was not achieved yet since C4 seems to be bound to 
plasma proteins and required the addition of hydrochloric acid in order to obtain 
sufficient recovery, which in turn would probably hydrolyse the gylcine and taurine 
moieties of conjugated species if the same procedure was applied to bile acids. 
 
 
3.3 Separation, ionisation and detection conditions 
 
The baseline separation of the two isomers CDCA and DCA as well as their glycine- 
and taurine-conjugates represented the main limitation for the chromatographic 
separation of the 15 bile acids since these isomers behave identically with respect to 
fragmentation and therefore they cannot be distinguished from each other by mass 
spectrometry only. Separation of the 15 major bile acids was consequently achieved 
in 20min. In the case of C4, the peak retention time was delayed to approximately 
8min because it needed to be separated from a 100 times more intense co-eluting 
peak of unknown origin in order to minimise ion suppression effects (data not 
shown). 
Selectivity is undeniably lower for unconjugated bile acids due to the absence of 
reproducible fragments, which was also the case in previously developed LC-MS 
methods for bile acids. However, the relevance of this analytical limitation depends 
on the context of the intended application. 
Examples of mass chromatograms of bile acids and C4 in serum from a healthy 
volunteer is shown in Figure 2. The total bile acid concentration in this serum 
reached 5.0μmol/l with GCDCA being the most concentrated species (1.4μmol/l), 
while the concentration obtained for C4 was 24.5nmol/l. 
ESI was chosen for the ionisation of bile acids since these molecules possess a 
carboxyl group (unconjugated and glycine-conjugated bile acids) or a sulfonyl group 
(taurine-conjugated bile acids) which easily generates negatively charged ions in 
solution. Ionisation of C4 was also performed using ESI although atmospheric 
pressure chemical ionisation (APCI) would probably have been a better suited 
ionisation technique regarding the polarity of the analyte. Nevertheless, ESI was 
preferred because it offered the possibility of combined application of both methods 
in addition to a sufficient sensitivity for the analysis of C4. The combined application 
of both methods represents an advantage, particularly for the analysis of large 
batches of samples. Indeed, the fact that both methods require the same eluents, 
stationary phase and ionisation source allows to run sequences containing both 
types of samples without any modifications of hardware (column, source), thereby 
sparing time and reducing the risk of handling errors. 
 
 
3.4 Method validation 
 
3.4.1 Linearity 
 
The calibration curves were linear in both calibration ranges for the 15 bile acids and 
C4. For the bile acids, the mean correlation coefficients r (n = 6) ranged from 0.9983 
to 1.0000 for the lower calibration domain (0.02-5μmol/l) and from 0.9994 to 1.0000 
for the entire calibration domain (0.02-50μmol/l). Linearity was also observed if the 
calibration domain was extended to 100μmol/l for high concentrated samples (data 
not shown). For C4, the mean correlation coefficient r (n = 6) was 0.9993 for both the 
lower (0.01-0.05μmol/l) and the entire (0.01-0.4μmol/l) calibration domain. 
 3.4.2 Precision and accuracy 
 
Intra- and inter-day precision and accuracy data are summarized in Table 3. For bile 
acids, intra-day (inter-day) variation (n = 6) ranged from 0.3% to 4.8% (0.7% to 
11.9%). Intra-day (inter-day) accuracy (n = 6) ranged from 87.6% to 102% (84.7% to 
102%). For C4, intra-day (inter-day) variation (n = 6) was below or equal to 5.2% 
(3.6%). Intra-day (inter-day) accuracy (n = 6) was 89.1% and 98.4% (97.7% and 
98.3%) for the low and the high QCs respectively. The precision and accuracy data 
were within the interval set by the FDA concerning validation of bioanalytical methods 
[28]. 
 
3.4.3 Recovery 
 
The extraction recoveries (n = 6) of the different bile acids and C4 are shown in Table 
3. This experiment only took in account the efficiency of the extraction procedure per 
se and not the matrix effects which are discussed below. In this case, matrix effects 
were identical for all samples since serum samples spiked before extraction were 
compared to serum samples spiked after extraction. 
The extraction recoveries for bile acids ranged from 78.3% to 99.3% and were 
slightly higher for 30μmol/l than for 0.5μmol/l samples, which might be due to 
imprecision in low concentrated samples when correcting for endogenous amounts, 
since error is proportionally higher on low concentrations. However, this did not affect 
linearity as demonstrated in 3.4.1. 
Table 4 summarizes and compares extraction recoveries of the here and previously 
reported methods for the measurement of bile acids and C4. Extraction recoveries for 
bile acids were quite similar to those reported for other existing methods [16-
18,20,22-24]. The extraction recovery for C4 was found to be approximately 62%, 
which was markedly lower than for bile acids and for other C4 methods [12,14,25-
26]. This is presumably explained by its lipophilic properties and by the fact that the 
others methods used different sample preparation techniques (protein precipitation, 
liquid-liquid extraction followed by SPE, derivatisation and salting-out respectively). 
 
3.4.4 Limit of quantification 
 LOQ was defined as the lowest concentration at which the analyte could be 
quantified with a coefficient of variation below 20% and accuracy between 80% and 
120% (n = 5). For bile acids, LOQ ranged from 2nmol/l to 50nmol/l. After correction 
for sample volume, this was comparable or slightly better than what has been 
reported in recent publications providing LOQ values [16,18-20,23-24] (Table 4). For 
C4, LOQ was 5nmol/l, which is similar to what was reported by DeBarber et al. [25]. 
The detailed LOQ values for the individual analytes are shown in Table 5. 
 
3.4.5 Matrix effects 
 
The results of the quantitative matrix effects test (n = 3) are shown in Table 6. In 
contrast to recovery, this experiment takes into account only the matrix effects (and 
not the loss that occurs during extraction) since the analytes were added to the 
matrix after extraction and compared to the same amount of analytes in pure 
solvents. 
The signal in presence of matrix components was between 73% and 103% of the 
signal in pure standards for all analytes, which indicated some competition between 
the analytes and interfering matrix components during ionisation. However, 
assessment of matrix effects in a qualitative way with post-column infusion of the 
analytes showed no significant ion suppression or enhancement effects in relevant 
detection timeframes, as demonstrated in Figure 3. 
In this paper, recovery and matrix effects were evaluated in separate experiments 
(2.9.3 and 2.9.5) unlike in some publications where recovery is assessed by 
comparing an extracted spiked sample to a stock solution. In this latter case, it would 
not be clear whether a decrease in signal intensity is due to insufficient extraction 
recovery or to ion suppression. 
 
 
3.5 Quantification of bile acids and C4 in a patient with cirrhosis and 
cholestasis 
 
As an application example, bile acids and C4 were quantified in the serum of a 39-
year old woman suffering from liver cirrhosis and cholecystolithiasis (gallstones) 
among other conditions (Figure 4). Clinical findings showed increased levels of total 
bilirubin (32μmol/l), gamma-glutamyl transferase (356U/l) and alkaline phosphatase 
(189U/l), which indicate the presence of cholestasis and liver damage. The total bile 
acid concentration in this patient was 10 times higher than in the serum from a 
healthy volunteer displayed in Figure 2 (56.5μmol/l versus 5.0μmol/l), which is often 
observed in cholestatic conditions. While glycine and taurine conjugates of the 
primary bile acids (GCA, GCDCA, TCA and TCDCA) showed up to an 80-fold 
increase in concentration compared to serum from a healthy volunteer, all secondary 
bile acids except GUDCA had concentrations below LOQ. Several of them (GDCA, 
TDCA and TLCA) were totally absent from the circulation as a consequence of 
breakdown of enterohepatic circulation. The concentration obtained for C4 was 
1.2nmol/l, (<LOQ) and indicates poor liver function due to cirrhosis, as C4 
concentrations in healthy subjects have been reported to be between 12nmol/l and 
120nmol/l (5-48ng/ml) [14]. 
 
 
4. Conclusions 
 
 
In addition to their traditionally recognized role in lipid emulsification, bile acids were 
found to be biologically important signaling molecules, which has resulted in an 
increased relevance of these metabolites in biology and medicine and in a greater 
demand for sensitive, precise and accurate methods for the quantification of bile 
acids in recent years. 
In this paper, we described two new methods based on LC-MS/MS for the combined 
quantification of the 15 major human bile acids and their precursor for the classical 
biosynthesis pathway, namely C4, in serum. The advantage of these methods lies in 
their ability to describe both the composition of the circulating bile acid pool and the 
amount of newly synthesised bile acids, reflected by C4 concentrations. Combination 
of both methods is possible since the eluents for the mobile phase, the stationary 
phase as well as the ionisation source are identical. These new methods allow 
detailed insight into bile acid metabolism in humans, which will provide additional 
valuable information while performing clinical studies to determine the prognostic 
and/or diagnostic value of cholesterol metabolites in various diseases. 
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7. Figure captions 
 
 
Figure 1: Structures of a) the major unconjugated, glycine- and taurine-conjugated 
bile acids and b) the bile acid precursor C4 
 
 
Figure 2: Representative chromatograms of an extracted serum (100μl) from a 
healthy volunteer, spiked with a) 7 deuterated bile acids (30μl, 15μmol/l) and showing 
endogenous amounts of the 15 major bile acids; b) C4-d7 (50μl, 0.1μmol/l) and 
showing endogenous amounts of C4. 
The total bile acid concentration represented 5.0μmol/l, whereas the C4 
concentration was 24.5nmol/l. 
RT: retention time (min), PI: peak intensity 
 
 
Figure 3: Qualitative assessment of matrix effects for the 15 bile acids and C4. The 
figure shows the effect of an extracted serum matrix on the signal of directly infused 
analytes for a) unconjugated bile acids; b) glycine-conjugated bile acids; c) taurine-
conjugated bile acids and d) C4. Chromatograms of standard stock solutions (bile 
acids: 10μl, 10μmol/l; C4: 10μl, 1μmol/l) were superimposed to facilitate visualisation 
of relevant detection timeframes. Concentrations and flow rates of the infused 
solutions were chosen as the minimum still covering the signal of endogenous peaks 
and are reported for every compound. 
 
 
Figure 4: Chromatograms of an extracted serum (100μl) from a patient suffering 
from liver cirrhosis and cholecystolithiasis spiked with a) 7 deuterated bile acids 
(30μl, 15μmol/l); b) C4-d7 (50μl, 0.1μmol/l). 
The total bile acid concentration represented 56.5μmol/l, whereas the C4 
concentration was 1.2nmol/l (<LOQ). 
RT: retention time (min), PI: peak intensity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
Table 1 
Parent and product ions of the analytes with individually optimised detection parameters (tube 
lens and collision energy) as well as corresponding internal standard used for quantification. 
If more than one fragment was reported, the sum of the signals of the different product ions 
was used for quantification.  
 
Bile acids Parent ion 
[M-H]- (m/z) 
Product ion 
[M-H]- (m/z) 
Tube lens 
(V) 
Collision energy 
(eV) 
Internal standard 
CA 407.2 407.2 -135 15 CA-d4 
      
CDCA 391.2 391.2 -135 15 CDCA-d4 
      
DCA 391.2 391.2 -135 15 DCA-d4 
      
LCA 375.2 375.2 -125 20 LCA-d4 
      
UDCA 391.2 391.2 -135 15 UDCA-d4 
      
GCA 464.2 464.2 -120 15 GCA-d4 
 464.2   74.4 -120 38  
      
GCDCA 448.2 448.2 -110 15 GCDCA-d4 
 448.2 404.1 -110 32  
 448.2 386.1 -110 35  
 448.2   74.4 -110 35  
      
GDCA 448.2 448.2 -110 15 DCA-d4 
 448.2 404.1 -110 32  
 448.2 386.1 -110 35  
 448.2   74.4 -110 35  
      
GLCA 432.2 432.2 -105 10 LCA-d4 
 432.2 388.1 -105 34  
 432.2   74.4 -105 38  
      
GUDCA 448.2 448.2 -110 15 UDCA-d4 
 448.2 404.1 -110 32  
 448.2 386.1 -110 35  
 448.2   74.4 -110 35  
      
TCA 514.2 514.2 -145 15 CA-d4 
 514.2 124.2 -145 46  
 514.2 107.2 -145 50  
      
TCDCA 498.2 498.2 -135 20 CDCA-d4 
 498.2 124.2 -135 47  
 498.2 107.2 -135 50  
      
TDCA 498.2 498.2 -135 20 DCA-d4 
 498.2 124.2 -135 47  
 498.2 107.2 -135 50  
      
TLCA 482.2 482.2 -135 15 LCA-d4 
 482.2 124.2 -135 45  
 482.2 107.2 -135 50  
      
TUDCA 498.2 498.2 -135 20 UDCA-d4 
 498.2 124.2 -135 47  
 498.2 107.2 -135 50  
      
CA-d4 411.2 411.2 -135 15 - 
      
CDCA-d4 395.2 395.2 -135 15 - 
      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Optimised ionisation and detection parameters and polarity for the 15 bile acids and C4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DCA-d4 395.2 395.2 -135 15 - 
      
LCA-d4 379.2 379.2 -125 15 - 
      
UDCA-d4 395.2 395.2 -135 15 - 
      
GCA-d4 468.2 468.2 -120 15 - 
 468.2   74.3 -120 38  
      
GCDCA-d4 452.2 452.2 -110 10 - 
 452.2   74.3 -110 38  
C4 Parent ion 
[M+H]+ (m/z) 
Product ion 
[M+H]+ (m/z) 
Tube lens 
(V) 
Collision energy 
(eV) 
Internal standard 
C4 401.3 383.3 108 16 C4-d7 
 401.3 177.0 108 23  
      
C4-d7 408.3 390.3 109 16 - 
 408.3 177.0 109 24  
Optimised parameter Unit bile acids C4 
Ionisation polarity - negative positive 
Spray voltage kV 4.0 5.0 
Sheath gas arbitrary 35 40 
Auxiliary gas arbitrary 10 35 
Ion sweep gas arbitrary 10 0 
Ion transfer capillary temperature °C 350 310 
Skimmer offset V 10 -5 
Table 3 
Precision, accuracy and recovery data for the 15 bile acids and C4 (n = 6) 
CV: coefficient of variation 
 
 
 
 
 
 
 
Analyte Nominal  Intra-day (n = 6)  Inter-day (n = 6)  Extraction 
 concentration  Mean CV Accuracy  Mean CV Accuracy  recovery 
 [μmol/l]  [μmol/l] [%] [%]  [μmol/l] [%] [%]  [%] 
CA   0.5    0.483   2.2   96.6    0.496   2.0   99.2  91.2 
 30.0  30.0   0.6 100  30.0   0.7   99.9  96.4 
            
CDCA   0.5    0.474   3.6   94.7    0.470   2.6   94.0  82.5 
 30.0  29.9   0.9   99.7  29.9   1.4   99.6  96.7 
            
DCA   0.5    0.479   3.6   95.9    0.470   2.6   93.9  88.4 
 30.0  30.0   0.5 100  29.8   1.9   99.2  98.4 
            
LCA   0.5    0.438   4.2   87.6    0.423   7.4   84.7  78.3 
 30.0  29.2   2.9   97.2  29.2   6.1   97.2  99.0 
            
UDCA   0.5    0.493   1.2   98.6    0.490   2.0   98.1  92.1 
 30.0  29.9   0.8   99.7  29.9   1.0   99.6  97.3 
            
GCA   0.5    0.485   1.7   97.0    0.496   1.4   99.2  92.1 
 30.0  29.8   0.3   99.4  30.1   0.8 100  99.1 
            
GCDCA   0.5    0.485   2.0   97.0    0.494   1.8   98.9  84.4 
 30.0  29.8   0.5   99.2  30.2   1.5 101  97.9 
            
GDCA   0.5    0.492   1.9   98.3    0.492   2.0   98.4  83.7 
 30.0  28.8   0.9   96.1  29.5   2.1   98.3  97.4 
            
GLCA   0.5    0.461   4.4   92.2    0.468 10.1   93.7  80.1 
 30.0  29.7   3.1   98.9  30.1   3.7 100  97.4 
            
GUDCA   0.5    0.483   2.2   96.6    0.497   1.0   99.4  92.4 
 30.0  30.7   0.8 102  30.6   1.4 102  96.7 
            
TCA   0.5    0.456   2.5   91.2    0.464   1.7   92.8  92.1 
 30.0  29.7   0.8   99.0  29.9   1.4   99.8  99.3 
            
TCDCA   0.5    0.471   2.2   94.3    0.481   2.9   96.1  85.5 
 30.0  29.6   0.6   98.7  30.0   1.7 100  98.9 
            
TDCA   0.5    0.475   2.4   95.0    0.486   2.5   97.3  85.8 
 30.0  29.7   0.9   98.9  29.9   1.8   99.6  98.1 
            
TLCA   0.5    0.479   4.8   95.7    0.489 11.9   97.8  82.7 
 30.0  28.7   3.5   95.5  29.2   5.0   97.2  96.5 
            
TUDCA   0.5    0.461   1.1   92.2    0.469   1.6   93.8  92.6 
 30.0  29.3   0.9   97.7  29.4   1.2   98.0  96.4 
            
C4   0.02    0.018   5.2   89.1    0.020   3.6   97.7  62.5 
   0.2    0.197   2.1   98.4    0.197   1.6   98.3  62.1 
Table 4 
Comparison of extraction recoveries, limit of quantification and sample volume between the 
new methods and methods previously described. LOQ values given in ng/ml were converted 
to nmol/l based on an average molecular mass of 400. LOQ values were extrapolated for a 
corresponding sample volume of 100µl in order to allow comparison between the methods. 
aLOQ was measured using a standard stock solution (in contrast to spiked sample matrix) 
n.r.: not reported 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bile acids     
Source Extraction 
recoveries 
Limit of Quantification 
(LOQ) 
Sample 
volume 
LOQ extrapolated to 
100µl sample volume 
 [%] [nmol/l] [ng/ml] [µl] [nmol/l] 
new method 78 - 99 2 – 50 n.r. 100 2 - 50 
[16] Xiang et al., 2010 88 - 103 5 n.r. 500 25 
[17] Scherer et al., 2009 > 80 n.r. n.r. 100 n.r. 
[18] Anouti et al., 2008 83 - 98 ~ 25 - 100 10 - 40 100 ~ 25 - 100 
[19] Bentayeb et al., 2008 n.r. ~ 1 - 400 ~ 0.4 - 160 100 ~ 1 - 400 
[20] Ye et al., 2007 86 - 110 3 - 18 n.r. 300 9 - 54 
[21] Ando et al., 2006 n.r. n.r. n.r. 100 n.r. 
[24] Burkard et al., 2005 85 - 105 1 - 103 n.r. 750 7.5 - 770 
[22] Tagliacozzi et al., 2003 93 - 105 n.r. n.r. 250 n.r. 
[23] Tessier et al., 2003 80 - 87 ~ 25 10 300 ~ 75 
C4     
Source Extraction 
recovery 
Limit of Quantification 
(LOQ) 
Sample 
volume 
LOQ extrapolated to 
100µl sample volume 
 [%] [nmol/l] [ng/ml] [µl] [nmol/l] 
new method 62 5 n.r. 100 5 
[25] DeBarber et al., 2010 79 - 105 125 50 5 6.25 
[12] Camilleri et al., 2009 93 - 107 n.r. n.r. 200 n.r. 
[26] Honda et al., 2007 92 - 94 0.25 a 0.1 a 50 0.125 a 
[14] Lövgren-Sandblom et al., 2007 105 n.r. n.r. 500 - 1000 n.r. 
Table 5 
Limit of quantification values for the 15 bile acids and C4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Limit of quantification 
 [nmol/l] 
CA 20 
CDCA 20 
DCA 20 
LCA 50 
UDCA 20 
GCA 20 
GCDCA 20 
GDCA 20 
GLCA 50 
GUDCA   5 
TCA   5 
TCDCA   5 
TDCA   2 
TLCA   5 
TUDCA   2 
C4   5 
Table 6 
Quantitative assessment of matrix effects for the 15 bile acids and C4 as well as for their 
internal standards (n = 3). The analytical response in presence of matrix was expressed as a 
percentage of the analytical response in the absence of matrix. 
CV: coefficient of variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Relative analytical response CV 
 [%] [%] 
CA   92.6 4.0 
CDCA   93.8 1.9 
DCA   92.0 2.8 
LCA   96.9 6.2 
UDCA   76.3 5.6 
GCA   93.2 4.4 
GCDCA 101 1.6 
GDCA 100 3.0 
GLCA   96.4 3.0 
GUDCA   87.5 6.0 
TCA   82.1 4.0 
TCDCA   94.6 2.6 
TDCA   97.3 3.4 
TLCA 103 2.3 
TUDCA   73.7 6.6 
C4   96.2 8.5 
   
CA-d4   91.7 2.9 
CDCA-d4   94.0 1.4 
DCA-d4   92.7 1.9 
LCA-d4 102 7.7 
UDCA-d4   78.2 6.0 
GCA-d4   92.0 3.8 
GCDCA-d4 101 1.9 
C4-d7   87.9 8.4 
